Dysplasia

Ibex Presents New Data from Multiple Studies Showcasing Accuracy of AI in Prostate, Breast and Gastric Cancer Diagnosis

Retrieved on: 
星期四, 三月 21, 2024
Diagnosis, Champalimaud Foundation, Cone Health Women's Hospital, PPV, Glomus tumor, Adenoma, Overdiagnosis, Incidence, Research, Cancer, Hospital, UPMC, Breast, Marie Cassidy, AI, University, Laboratory, MD, Oncology, Medicine, USCAP, OSU, Dysplasia, Brigham and Women's Hospital, Breast cancer, Ohio State University, Pathology, Champalimaud, Stomach, Artificial intelligence, Annual general meeting, NPV, Medical imaging

BOSTON, March 21, 2024 /PRNewswire/ -- Ibex Medical Analytics (Ibex), the leader in AI-powered cancer diagnostics, today announced excellent results across multiple clinical studies conducted with the University of Pittsburgh Medical Center (UPMC), Brigham and Women's Hospital, Champalimaud Foundation and Ohio State University (OSU). These studies, highlighting the value of Ibex's AI-powered cancer diagnostics solutions in both diagnostic quality and efficiency, will be presented next week at the United States and Canadian Academy of Pathology (USCAP) Annual Meeting.

Key Points: 
  • Brigham and Women's Hospital and Champalimaud Foundation research shows high accuracy levels of Galen Breast in identifying microinvasive carcinoma of the breast.
  • Ohio State University Wexner Medical Center studies show high accuracy for Galen Breast and Galen Gastric in detecting and distinguishing between different types of cancer and in identifying multiple important pathologies.
  • In addition, researchers from OSU Wexner Medical Center will present studies validating Galen Breast's performance in detecting different types of breast cancer.
  • Ibex will be showcasing these findings at the USCAP Annual Meeting taking place in Baltimore, Maryland, between March 23 to 28, at booth number 755.

Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens

Retrieved on: 
星期二, 三月 5, 2024
Oncology, Medical Supplies, Health, Medical Devices, Research, Science, Biotechnology, Methylation, Cervical cancer, Woman, ASCL1, Dysplasia, Triage, Partnership, Multiple endocrine neoplasia, Test management, Human papillomavirus infection, Fujirebio, Risk, SCC, Biomarker, RUO, Incidence, Patient, Carcinoma, Carcinogenesis, Gene, HPV, HSIL, Host, Anal cancer, Lithium, DNA methylation, DNA, IVD, Cancer, CIN, Vaccine

Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.

Key Points: 
  • Also in this HPV-related cancer, methylation appears to be promising for future use as an accurate biomarker for objective risk stratification of anal lesions.
  • In analogy with cervical cancer screening, the screening and treatment of HSIL to prevent anal cancer in high-risk groups are under debate.
  • Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial neoplasia and anal cancer.
  • Analytical validation and diagnostic performance of the ASCL1/ZNF582 methylation test for detection of high-grade anal intraepithelial neoplasia and anal cancer.

Advancing Precision in Barrett's Esophagus and Dysplasia Diagnoses: WATS3D Study Demonstrates Exceptional Consensus Among Pathologists

Retrieved on: 
星期三, 三月 6, 2024
Consensus, HGD, Dysplasia, Goldblum, LGD, Cleveland Clinic, Marie Cassidy, CDX, Doctor of Philosophy, Intraepithelial neoplasia, Brigham and Women's Hospital, Barrett's esophagus, Hospital, Diagnosis, Mayo Clinic, Health, Patient, EAC, MPH, Clinical and Translational Gastroenterology, Esophageal cancer, Neoplasm, Yale School of Medicine, Esophagus, Gastroenterology, Tufts Medical Center, Medical imaging

WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.

Key Points: 
  • WATS3D Study Demonstrates Exceptional Consensus Among Pathologists.
  • This was a collaborative study among gastrointestinal pathologists who have an interest and expertise in Barrett's esophagus.
  • The pathologists were then asked to evaluate digital images from 60 WATS3D cases with BE.
  • "The significant variability among pathologists assessing Barrett's esophagus poses challenges for accurate diagnosis and treatment decisions, complicating patient care."

Castle Biosciences to Present New Data on its TissueCypher® Barrett’s Esophagus Test at the 2023 American College of Gastroenterology Annual Scientific Meeting

Retrieved on: 
星期二, 十月 24, 2023
Research, Genetics, Biotechnology, Other Health, Health, General Health, Other Science, Science, Oncology, Patient, EAC, American College, IND, Identity, New York University Grossman School of Medicine, Medicare, Physician, ACG, Pathology, Cancer, BE, University School, Dysplasia, Geisinger Commonwealth School of Medicine, Risk, American College of Gastroenterology, LGD, HGD, Geisinger Medical Center, Diagnosis, Nursing, Medical imaging, Medicine

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher® test in patients with Barrett’s esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver, Canada.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will highlight the impactful risk stratification provided by its TissueCypher® test in patients with Barrett’s esophagus (BE) through two posters at the 2023 American College of Gastroenterology (ACG 2023) Annual Scientific Meeting, taking place Oct. 20-25, in Vancouver, Canada.
  • “However, we find that at least half of the patients who progress to EAC come from this “low-risk” population, which tells us that there is a critical need to improve our risk-stratification of these patients.
  • In patients with higher-risk clinicopathologic factors (males with a pathology diagnosis of indefinite for dysplasia (IND) or LGD), TissueCypher identified low-risk patients with predicted progression rates similar to patients with NDBE.
  • Overall, the data show the risk stratification provided by the TissueCypher test can aid physicians and patients in making risk-aligned patient management decisions, such as escalated or de-escalated care, which may lead to improved health outcomes.

Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus

Retrieved on: 
星期一, 十月 2, 2023
Oncology, Health, Surgery, Managed Care, Research, Science, Biotechnology, LGD, AFS, Esophagus, Cancer, Radiofrequency ablation, EAC, Incidence, BE, HGD, Dysplasia, HIV disease progression rates, Patient, Physician, Risk, Report, Annual general meeting, Esophageal cancer, Poster, EET, RFA, Pharmaceutical industry, Medical imaging

The data was presented in a poster at the recent American Foregut Society (AFS) Annual Meeting.

Key Points: 
  • The data was presented in a poster at the recent American Foregut Society (AFS) Annual Meeting.
  • The poster, titled “A Tissue Systems Pathology Test Enables Risk-Aligned Management of Patients with Non-Dysplastic Barrett’s Esophagus: Case Reports from a Gastrointestinal Surgery Center,” can be viewed here .
  • The case study reinforced the ability of TissueCypher to identify NDBE patients at high/intermediate risk for progression to HGD/EAC.
  • Identification of NDBE patients with similar progression risk to LGD enables physicians and their patients to consider risk-aligned upstaging of care to prevent development of EAC and improve their overall health outcomes.

TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus

Retrieved on: 
星期四, 九月 14, 2023
Oncology, Health, Genetics, Other Health, Clinical Trials, Research, Science, University, LGD, Marie Cassidy, SURF, Pathology, Cancer, Radiofrequency ablation, EAC, BE, HGD, Dysplasia, Patient, Standard of care, Physician, Surveillance, Esophageal cancer, Artificial intelligence, Diagnosis, Disease, Medical device, Medical imaging, Gastroenterology

The study aimed to compare the test’s performance against an international panel of 14 expert and 16 community-based, generalist pathologists from five countries.

Key Points: 
  • The study aimed to compare the test’s performance against an international panel of 14 expert and 16 community-based, generalist pathologists from five countries.
  • Use of the TissueCypher test in combination with pathology review identified 80.4% of patients who progressed, indicating that the test can increase the early detection of progressors when used with pathology.
  • Overall, the study demonstrated that TissueCypher can accurately predict progression to HGD or EAC in BE patients who are initially diagnosed with LGD in a community setting.
  • Further, TissueCypher test results can provide an objective solution to variable pathology review, allowing physicians to make more informed management decisions for their patients, which may include upstaging care for patients at high risk for progression and reducing unnecessary interventions in low-risk patients.

TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus

Retrieved on: 
星期五, 九月 8, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Male, Probability, LGD, Geisinger Medical Center, ISDE, Pathology, Cancer, Medicine, Geisinger Commonwealth School of Medicine, EAC, Congress, BE, HGD, Dysplasia, Physician, Risk, Diagnosis, IND, Pharmaceutical industry, Medical imaging, Patient

Most patients were male (61.8%), under surveillance in a community-based practice (94.9%) and had a diagnosis of non-dysplastic Barrett’s esophagus (NDBE) (95.1%), which is representative of the general BE patient population.

Key Points: 
  • Most patients were male (61.8%), under surveillance in a community-based practice (94.9%) and had a diagnosis of non-dysplastic Barrett’s esophagus (NDBE) (95.1%), which is representative of the general BE patient population.
  • Patients with NDBE are considered to be at low risk for progression based on their clinical risk factors.
  • These data demonstrate that TissueCypher provided impactful risk stratification, independent of clinicopathologic risk factors, to enable risk-aligned management of BE patients.
  • This included objective information to support surveillance-only management for patients with a low risk of progression and escalated surveillance/treatment for patients at high risk of progression.

The BioInnovation Institute welcomes eight new companies to its Venture Lab program

Retrieved on: 
星期四, 八月 31, 2023
Laboratory, Lead poisoning, Novozymes, Cancer, Research, Immunotherapy, Wilson, Wilson's disease, EUR, Dysplasia, Patient, Corporation, HPV, Knowledge, Diagnosis, BII, Therapy, Human papillomavirus infection, Pharmaceutical industry, Medical imaging

COPENHAGEN, Denmark, Aug. 31, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that eight new companies have entered its Venture Lab acceleration program for early-stage companies.

Key Points: 
  • COPENHAGEN, Denmark, Aug. 31, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that eight new companies have entered its Venture Lab acceleration program for early-stage companies.
  • In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII's Venture House program.
  • Bobby Soni, Chief Business Officer at BioInnovation Institute, said: "These eight early-stage companies are a fantastic addition to BII's Venture Lab.
  • The new companies BII has accepted into the Venture Lab acceleration program are:
    Loma Therapeutics is developing targeted immunotherapy for efficient and safe treatment of patients with HPV infection, dysplasia, and cancer.

The BioInnovation Institute welcomes eight new companies to its Venture Lab program

Retrieved on: 
星期四, 八月 31, 2023
Laboratory, Lead poisoning, Novozymes, Cancer, Research, Immunotherapy, Wilson, Wilson's disease, EUR, Dysplasia, Patient, Corporation, HPV, Knowledge, Diagnosis, BII, Therapy, Human papillomavirus infection, Pharmaceutical industry, Medical imaging

COPENHAGEN, Denmark, Aug. 31, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that eight new companies have entered its Venture Lab acceleration program for early-stage companies.

Key Points: 
  • COPENHAGEN, Denmark, Aug. 31, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that eight new companies have entered its Venture Lab acceleration program for early-stage companies.
  • In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive opportunity to apply for EUR 1.3M in follow-up funding through BII's Venture House program.
  • Bobby Soni, Chief Business Officer at BioInnovation Institute, said: "These eight early-stage companies are a fantastic addition to BII's Venture Lab.
  • The new companies BII has accepted into the Venture Lab acceleration program are:
    Loma Therapeutics is developing targeted immunotherapy for efficient and safe treatment of patients with HPV infection, dysplasia, and cancer.

New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus

Retrieved on: 
星期一, 八月 7, 2023
Science, Biometrics, Biotechnology, Research, Oncology, Health, Genetics, Other Health, University, LGD, Marie Cassidy, SURF, Pathology, Radiofrequency ablation, Gastrointestinal Endoscopy, Cancer, SOC, Incidence, BE, American Journal, The American Journal of Gastroenterology, Dysplasia, Patient, Standard of care, Risk, Surveillance, Mortality, Nursing, Pharmaceutical industry, IND

The full study is available here .

Key Points: 
  • The full study is available here .
  • The study results showed the following:
    Using TissueCypher test results to guide patient management decisions, in conjunction with the standard of care (SOC), significantly increased the likelihood of patients receiving appropriate management per their known outcome.
  • Overall, the study results suggest that TissueCypher may be used to standardize the management of BE patients with NDBE, IND and LGD.
  • Use of the TissueCypher test may also improve health outcomes by identifying patients at a low risk of progression who can avoid unnecessary therapy and be managed using surveillance alone.